Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc

Cancer shared this article with you from Inoreader Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc Via Latest Results for Molecular Cancer Abstract c-Myc is a transcription factor that is constitutively and aberrantly expressed in over 70% of human cancers. Its direct inhibition has been shown to trigger rapid tumor regression in mice with only mild and fully reversible side effects, suggesting this to be a viable therapeutic strategy. Here we reassess the challenges of directly targeting c-Myc, evaluate lessons learned from current inhibitors, and explore how future strategies such as miniaturisation of Omomyc and targeting E-box binding could facilitate translation of c-Myc inhibitors into the clinic. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.